Maria Maccecchini - Annovis Bio CEO
| ANVS Stock | USD 5.96 0.30 5.30% |
CEO
Maria Maccecchini is President, Chief Executive Officer, Founder, Director of Annovis Bio since 2008.
| Age | 73 |
| Tenure | 16 years |
| Address | 101 Lindenwood Drive, Malvern, PA, United States, 19355 |
| Phone | (484) 875-3192 |
| Web | https://www.annovisbio.com |
Maria Maccecchini Latest Insider Activity
Tracking and analyzing the buying and selling activities of Maria Maccecchini against Annovis Bio stock is an integral part of due diligence when investing in Annovis Bio. Maria Maccecchini insider activity provides valuable insight into whether Annovis Bio is net buyers or sellers over its current business cycle. Note, Annovis Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Annovis Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Maria Maccecchini over a month ago Acquisition by Maria Maccecchini of 21312 shares of Annovis Bio subject to Rule 16b-3 | ||
Maria Maccecchini over six months ago Disposition of 3000 shares by Maria Maccecchini of Annovis BioInc subject to Rule 16b-3 | ||
Maria Maccecchini over a year ago Bona fide gift to Maria Maccecchini of 3000 shares of Annovis BioInc subject to Section 16 |
Annovis Bio Management Efficiency
The company has return on total asset (ROA) of (1.5458) % which means that it has lost $1.5458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.967) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 7.61 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23). At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23).Similar Executives
| Found 9 records | CEO Age | ||
| John MBA | Novavax | 57 | |
| MSc JD | Cue Biopharma | 63 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Stanley Erck | Novavax | 76 | |
| Panna Sharma | Lantern Pharma | 53 | |
| Clay Siegall | Immunome | 63 | |
| Daniel MBA | Acumen Pharmaceuticals | 54 | |
| Eric MBA | Seres Therapeutics | 48 | |
Management Performance
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 |
Annovis Bio Leadership Team
Elected by the shareholders, the Annovis Bio's board of directors comprises two types of representatives: Annovis Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Annovis. The board's role is to monitor Annovis Bio's management team and ensure that shareholders' interests are well served. Annovis Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Annovis Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hilda Maibach, Senior Statistics | ||
| Michael Hoffman, Independent Director Chairman of the Board | ||
| Jeffrey McGroarty, Chief Financial Officer | ||
| RAC MS, Senior Operations | ||
| Claudine Bruck, Independent Director | ||
| Maria Maccecchini, President, Chief Executive Officer, Founder, Director | ||
| MBA III, Chief Officer | ||
| Blake Jensen, Head Quality | ||
| Reid McCarthy, Independent Director | ||
| Cheng Fang, Senior Development | ||
| Melissa Gaines, Senior Operations | ||
| Mark White, Independent Director |
Annovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Annovis Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 | ||||
| Current Valuation | 66.42 M | ||||
| Shares Outstanding | 13.8 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 8.83 % | ||||
| Number Of Shares Shorted | 1.31 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 11.19 X | ||||
| EBITDA | (45.04 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.